Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D0R8LN
|
||||
| Former ID |
DNC009920
|
||||
| Drug Name |
N-{4-[2-(3-Methoxyphenyl)ethyl]phenyl}phthalimide
|
||||
| Drug Type |
Small molecular drug
|
||||
| Indication | Discovery agent | Investigative | [1] | ||
| Structure |
|
Download2D MOL |
|||
| Formula |
C23H19NO3
|
||||
| Canonical SMILES |
COC1=CC=CC(=C1)CCC2=CC=C(C=C2)N3C(=O)C4=CC=CC=C4C3=O
|
||||
| InChI |
1S/C23H19NO3/c1-27-19-6-4-5-17(15-19)10-9-16-11-13-18(14-12-16)24-22(25)20-7-2-3-8-21(20)23(24)26/h2-8,11-15H,9-10H2,1H3
|
||||
| InChIKey |
CNZNMDJWLSHLJZ-UHFFFAOYSA-N
|
||||
| PubChem Compound ID | |||||
| Target and Pathway | |||||
| Target(s) | Oxysterols receptor LXR-beta | Target Info | Inhibitor | [1] | |
| Oxysterols receptor LXR-alpha | Target Info | Inhibitor | [1] | ||
| KEGG Pathway | PPAR signaling pathway | ||||
| Non-alcoholic fatty liver disease (NAFLD) | |||||
| Hepatitis C | |||||
| Pathway Interaction Database | RXR and RAR heterodimerization with other nuclear receptorrxr_vdr_pathway:RXR and RAR heterodimerization with other nuclear receptor | ||||
| Reactome | Nuclear Receptor transcription pathway | ||||
| WikiPathways | SREBP signalling | ||||
| Nuclear ReceptorsWP299:Nuclear Receptors in Lipid Metabolism and Toxicity | |||||
| Nuclear Receptors Meta-Pathway | |||||
| PPAR Alpha Pathway | |||||
| Liver X Receptor Pathway | |||||
| Adipogenesis | |||||
| SREBF and miR33 in cholesterol and lipid homeostasis | |||||
| Nuclear Receptors | |||||
| References | |||||
| REF 1 | Bioorg Med Chem. 2009 Jul 15;17(14):5001-14. Epub 2009 Jun 2.Separation of alpha-glucosidase-inhibitory and liver X receptor-antagonistic activities of phenethylphenyl phthalimide analogs and generation of LXRalpha-selective antagonists. | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.